Pasithea Therapeutics Reported In-line with Estimates

Pasithea Therapeutics (KTTA) reported a loss of $0.16 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.16 per share. The company reported in-line with consensus estimates.

Pasithea Therapeutics Corp. is a biotechnology company. It focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is based in MIAMI BEACH, Fla.